Hua Xu, Principal Scientist at Pfizer, to Present at Drug Design & Medicinal Chemistry Mtg
Summary
Boston, MA, July 19, 2016 --( Phenotypic screening is a major source for the discovery of first-in-class small molecule drugs, thanks to its ‘target agnostic’ feature.Recent technology advances and utilization of patient-derived cells have facilitated the design of sophisticated phenotypic assays that recapitulate the disease relevant biology.New Opportunities for Computational Drug Design V. Big Data in Medicinal Chemistry For more information, please visit website: https://www.gtcbio.com/conferences/medicinal-chemistry-drug-design-overview GTCbio 635 W. Foothill Blvd Monrovia, CA 91016 www.gtcbio.com Email: infogtcbio@gtcbio.com Phone: (626) 256-6405 Fax: (626) 466-4433 Boston, MA, July 19, 2016 --( PR.com )-- Hua Xu, Principal Scientist of Worldwide Medicinal Chemistry at Pfizer, will give a presentation on, “Chemical Biology Tools for Target Identification” at GTCbio’s 11th Drug Design & Medicinal Chemistry to be held on September 12-13, 2016 in Boston, MAPhenotypic screening is a major source for the discovery of first-in-class small molecule drugs, thanks to its ‘target agnostic’ feature.Recent technology advances and utilization of patient-derived cells have facilitated the design of sophisticated phenotypic assays that recapitulate the disease relevant biology.These methods would be broadly useful for researchers to identify and validate potential targets for the compounds from phenotypic screens.This meeting will provide a forum for scientists across multiple disciplines, from both industry and academia, to connect and share complementary perspectives.